Home
Learn More
Features & Pricing
Success Stories
Contact Us
Search Archives
PRWeb Direct
Submit Release
September 7, 2008
 
Industry Categories  
News by Country  
News by MSA  
Todays News  
Browse by Day  
PR Trackbacks™  
Featured Videos  
ViewNews™  
eBook Digests  
RSS  
PRWeb, a leader in online news and press release distribution, has been used by more than 40,000 organizations of all sizes to increase the visibility of their news, improve their search engine rankings and drive traffic to their Web site.
 
All Press Releases for January 21, 2005 Subscribe to this News Feed      
 

BioWa Receives Milestone Payment from Medarex

BioWa, Inc. today announced that it has received an undisclosed milestone payment from its partner, Medarex, Inc.

Princeton, N.J (PRWEB) January 21, 2005 -- BioWa, Inc. today announced that it has received an undisclosed milestone payment from its partner, Medarex, Inc., under the license agreement for BioWas Potelligent Technology for the enhancement of Fc receptor mediated antibody activity a critical mechanism in tumor lysation and anti-cancer therapy. BioWa may receive future milestone payments and royalties in the event that products advance to clinical stage development.

"Medarex is a leader in the discovery and development of fully human antibody-based therapeutics and a key strategic partner to BioWa in developing PotelligentTM enhanced antibodies. This milestone achievement reinforces BioWa's mission to create the ultimate therapeutic antibodies available to treat life-threatening diseases, such as cancer, as quickly as possible. We are very pleased of this expansion of our relationship and Medarexs achievements," said Dr. Nobuo Hanai, President and CEO of BioWa.

About BioWa, Inc.
BioWa is a wholly owned subsidiary of Kyowa Hakko Kogyo Co, Ltd, Japans leading pharmaceutical and largest biotech company. BioWa is the exclusive worldwide licensor of Potelligent Technology. Potelligent Technology creates high antibody-dependent cellular cytotoxicity (ADCC) monoclonal antibodies. ADCC is a critical function of the immune system that enhances the ability of antibodies to kill tumor cells. The enhancement of ADCC is seen up to 100 fold in vitro. Both BioWa and Kyowa Hakko are currently developing ADCC enhanced monoclonal antibody-based therapeutics to fight cancer and other life threatening and debilitating diseases in various clinical stages. BioWa creates and develops enhanced ADCC antibodies for itself and others, offering a full range of antibody discovery and development capabilities. For more information about BioWa visit its web site at www.biowa.com.

Potelligent is the registered trademark of of Kyowa Hakko Kogyo Co., Ltd. All rights are reserved.

# # #

Technorati Tags

Bookmark -  Del.icio.us | Digg | Furl It | Spurl | RawSugar | Simpy | Shadows | Blink It | My Web


OPTIONS
Printer Friendly Version
Download PDF Version
Download Reader Version
Email this story to a colleague
CONTACT INFORMATION
Martina Molsbergen
BIOWA INC.
609 580-7506
Email us Here
ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files through your login.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these releases. Our complete disclaimer appears here.
 
Disclaimer: If you have any questions regarding information in these press releases please contact the company listed in the press release.
Please do not contact PRWeb®. We will be unable to assist you with your inquiry.
PRWeb® disclaims any content contained in these releases. Our complete disclaimer appears here.

© Copyright 1997-2008, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Terms of Service | Privacy Policy | Copyright